Proteomic Analysis of Human Endometrial Tissues Reveals the Roles of PI3K/AKT/mTOR Pathway and Tumor Angiogenesis Molecules in the Pathogenesis of Endometrial Cancer

被引:18
|
作者
Liu, Zhen [1 ,2 ,3 ]
Hong, Zhipan [4 ]
Qu, Pengpeng [3 ]
机构
[1] Tianjin Med Univ, Dept Obstet & Gynecol, Tianjin 300070, Peoples R China
[2] Inner Mongolia Med Univ, Chifeng Clin Med Sch, Chifeng Municipal Hosp, Dept Gynecol, Chifeng 024000, Peoples R China
[3] Tianjin Cent Hosp Gynecol & Obstet, Dept Gynecol Oncol, Tianjin 300070, Peoples R China
[4] Inner Mongolia Med Univ, Chifeng Municipal Hosp, Dept Tumor Surg, Chifeng Clin Med Sch, Chifeng 024000, Peoples R China
关键词
ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; OSTEOPONTIN; ENVIRONMENT; PROTEINS; CATENIN; PI3K;
D O I
10.1155/2020/5273969
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
As one major gynecological malignancy, endometrial cancer (EC) has been widely studied recently. However, its pathogenesis is still unclear to date. In this study, we identified differentially expressed proteins between 30 endometrial cancer tissues and 30 matched normal controls using 2D LC-MS/MS quantitative proteomics. As a result, we identified 619 differentially expressed proteins among all 2521 proteins being quantified. Further analyses suggested that the changes of fat, amino acid metabolism, peroxisome, extracellular signal, cytoskeleton, and other signaling or metabolic pathways may be closely related to the development of this cancer. Particularly, the PI3K/AKT/mTOR pathway-related molecules including PI3K and mTOR, ERK (the molecule of the ERK pathway), SPP1, and ANGPT2 (angiogenesis-related molecules) are highly associated with the pathogenesis of EC, which were reconfirmed by western blot and immunohistochemistry (IHC) analysis. In summary, our study revealed that the PI3K/AKT/mTOR pathway and tumor angiogenesis molecules contribute to the pathogenesis of endometrial cancer.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis
    McAuliffe, Priscilla F.
    Meric-Bernstam, Funda
    Mills, Gordon B.
    Gonzalez-Angulo, Ana M.
    CLINICAL BREAST CANCER, 2010, 10 : S59 - S65
  • [22] Characteristics and clinical correlations of PI3K/AKT/mTOR pathway genetic variations in Chinese endometrial carcinoma
    Xue, Fengxia
    Wang, Yingmei
    Wang, Haifang
    Zhang, Jun
    Meng, Li
    Guo, Honglin
    Shi, Junping
    CANCER RESEARCH, 2020, 80 (16)
  • [23] TARGETING ENDOMETRIAL STROMAL SARCOMA CELLS VIa HISTONE DEACETYLASE AND THE PI3K/AKT/MTOR PATHWAY
    Quai, Ping
    Moinfar, Farid
    Kufferath, Iris
    Absenger, Markus
    Kueznik, Tatjana
    Denk, Helmut
    Zatloukal, Kurt
    Haybaeck, Johannes
    ANTICANCER RESEARCH, 2014, 34 (10) : 5943 - 5944
  • [24] Involvement of the PI3K/Akt/mTOR Pathway in Controlling Chondrogenic Differentiation of Endometrial Mesenchymal Stromal Cells
    Brovkina A.S.
    Ushakov R.E.
    Vassilieva I.O.
    Domnina A.P.
    Burova E.B.
    Cell and Tissue Biology, 2022, 16 (2) : 130 - 139
  • [25] The PI3K/AKT pathway in the pathogenesis of prostate cancer
    Chen, Huixing
    Zhou, Lan
    Wu, Xiaorong
    Li, Rongbing
    Wen, Jiling
    Sha, Jianjun
    Wen, Xiaofei
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2016, 21 : 1084 - 1091
  • [26] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [27] JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer
    Qiu, Haifeng
    Li, Jing
    Clark, Leslie H.
    Jackson, Amanda L.
    Zhang, Lu
    Guo, Hui
    Kilgore, Joshua E.
    Gehrig, Paola A.
    Zhou, Chunxiao
    Bae-Jump, Victoria L.
    ONCOTARGET, 2016, 7 (41) : 66809 - 66821
  • [28] Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
    Musa, Fernanda
    Schneider, Robert
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) : 97 - 106
  • [29] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
  • [30] New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway-The Devil Is in the Details
    Myers, Andrea P.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5264 - 5274